Peter Wehrly, CEO of Synaptive Medical, Inc., has been named to the Board of Directors of Titan Spine, Inc. Wehrly’s appointment “provides the company with extensive medtech market knowledge and experience for the deployment of its nanoLOCK surface technology.”
According to Titan Spine, “Prior to his appointment as CEO of Synaptive in October 2017, Mr. Wehrly was Chairman of the Board of Directors and an advisor to Synaptive from 2015 to 2017. From April 2016 to August 2017, Mr. Wehrly served as the CEO of PQ Bypass, a company based in Sunnyvale, California focused on breakthrough technology for the treatment of peripheral arterial disease. Previously, he was the Group President of Developed Markets at Covidien, a medical device manufacturer with annual sales of over $10.7 billion that was acquired by Medtronic, Inc. in 2015. In this position, Peter held profit and loss responsibility for the marketing and sale of products to all developed markets outside the U.S. between 2013 and 2015.”
“Preceding this role, Peter was the Group President of Respiratory and Monitoring Solutions, Vascular Therapies, and for all of Covidien’s Japanese, Australian-New Zealand, and Canadian businesses. Prior to Covidien, Mr. Wehrly held the position of President and CEO at Medingo Youqneam, an Israel-based team that developed a novel insulin pump for diabetic patients. He also presided over Medtronic’s Spinal, Biologics, and Navigation businesses from 2004 to 2008. Peter started his career with DePuy, a Johnson & Johnson company.”
Peter Ullrich, M.D., CEO of Titan Spine, stated, “We recognize the importance of adding exceptional talent, guidance and expertise to our Board to help us continue driving Titan’s growth. Peter is a strategic leader who consistently delivers top-line growth and operational efficiencies across a wide range of global cultures. He has excelled in both public and private organizations, in both start-ups and multi-billion-dollar businesses, and in both developed and emerging markets. We are confident that Peter’s addition will advance our near and long-term goals for further building Titan Spine as the leader in surface technology medical devices.”
Wehrly told OTW, “I am thrilled to join Titan Spine as an independent Director on their Board and look forward to helping the organization continue to disrupt the spine industry with its unique technology based on validated science. The company has achieved strong revenue growth since its inception 12 years ago, which ultimately is a testament to how their products perform clinically.”
“My immediate task on the Board is to help lay out a long-term strategy for capital needs and structure that will allow the company to leverage its robust product portfolio, experienced management team, strong infrastructure and clinical data. The goal is to maximize the potential of Titan’s nanoLOCK surface as a platform technology that not only impacts the care of patients that need interbody fusions, but also patients in the broader spine and orthopedic markets.”
